Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Levofloxacin; Minocycline; Ofloxacin; Tigecycline

Criteria

Inclusion Criteria:

• Male and female subjects ≥ 18 years of age and in Bulgaria only ≤ 70 years of age

• Subjects hospitalized with CAP with a severity that requires IV antibiotic treatment for at least 7 days

• The presence of fever (within 24 hours before randomization)

Exclusion Criteria:

• Any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy could be completed (eg, life expectancy <30 days).

• Hospitalization within 14 days before the onset of symptoms.

• Residence in a long-term care facility or nursing home ≥14 days before the onset of symptoms.